Advertisement

Ondansetron Injection

[11 August 2016]

Products Affected - Description

Ondansetron injection, AuroMedics
2 mg/mL, 20 mL vial, 1 count (NDC 55150-0126-20)
 
Ondansetron injection, Teva
2 mg/mL, 20 mL vial, 1 count (NDC 00703-7226-01)
2 mg/mL, 20 mL vial, 10 count (NDC 00703-7226-03)

Reason for the Shortage

  • AuroMedics did not provide a reason for the shortage.
  • Fresenius Kabi had ondansetron injection on back order due to increased demand.
  • Heritage has new NDC numbers for ondansetron injection.
  • Hospira had ondansetron injection on shortage due to increased demand.
  • Sagent had ondansetron on back order due to increased demand.
  • The Medicines Company will no longer be supplying ondansetron.
  • West-Ward had ondansetron on back order due to increased demand.
  • Wockhardt has ondansetron injection on an FDA import alert.

Available Products

Zofran injection, Novartis
2 mg/mL, 20 mL vial, 1 count (NDC 00173-0442-00)
 
Ondansetron injection, AuroMedics
2 mg/mL, 2 mL vial, 25 count (NDC 55150-0125-02)
 
Ondansetron injection, BD Rx
2 mg/mL, 2 mL prefilled syringe, 24 count (NDC 76045-0103-20)
 
Ondansetron injection, Fresenius Kabi
2 mg/mL, 2 mL vial, 25 count (NDC 63323-0373-02)
2 mg/mL, 20 mL vial, 1 count (NDC 63323-0374-20)

Ondansetron injection, Heritage
2 mg/mL, 2 mL vial, 10 count (NDC 23155-0547-41)
2 mg/mL, 2 mL vial, 25 count (NDC 23155-0547-42)
2 mg/mL, 20 mL vial, 1 count (NDC 23155-0549-31)
 
Ondansetron injection, Hospira
2 mg/mL, 2 mL iSecure syringe, 10 count (NDC 00409-1120-12)
2 mg/mL, 2 mL vial, 25 count (NDC 00409-4755-03)
2 mg/mL, 20 mL vial, 1 count (NDC 00409-4759-01)
 
Ondansetron injection, Mylan Institutional
2 mg/mL, 2 mL vial, 25 count (NDC 67457-0441-20)
2 mg/mL, 20 mL vial, 1 count (NDC 67457-0440-20)
 
Ondansetron injection, Sagent
2 mg/mL, 2 mL vial, 25 count (NDC 25021-0777-02)
 
Ondansetron injection, Teva
2 mg/mL, 2 mL vial, 25 count (NDC 00703-7221-04)
 
Ondansetron injection, West-Ward
2 mg/mL, 2 mL vial, 25 count (NDC 00641-6078-25)
2 mg/mL, 20 mL vial, 1 count (NDC 00143-9890-01)
2 mg/mL, 20 mL vial, 1 count (NDC 00641-6079-01)

Estimated Resupply Dates

  • AuroMedics has ondansetron 2 mg/mL 20 mL vials on intermittent back order and the company is releasing product as it becomes available.
  • Teva has ondansetron 2 mg/mL 20 mL vials in 1 and 10 count on long-term back order and the company cannot estimate a return date.

Related Shortages

Updated

August 11, May 25 and 18, April 8, February 24, 22 and 4, 2016; December 3, November 11, October 28, September 29, June 26, May 22, April 30, March 11, February 19, January 23, 2015; December 22, November 17, October 29, September 24, August 21, July 7, June 13, April 28, March 31, February 5, January 24, 2014; December 12, November 20, October 23, August 14, July 2, June 19, May 30, February 6, January 11, 2013; December 13, November 28, October 26, September 19, August 3, July 25, June 28, May 25, April 24, March 28, February 29, January 20, 2012; December 16, November 23, October 27, September 30, July 29, June 30, May 23, March 18, January 21, 2011; December 22, October 15, September 10, August 11, June 1, February 8, 2010; December 15, October 23, September 25, August 11, July 1, May 20, April 17, March 11, February 27, January 23, 2009, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing